Equities

Sichuan Hebang Biotechnology Co Ltd

Sichuan Hebang Biotechnology Co Ltd

Actions
Basic MaterialsChemicals
  • Price (CNY)1.40
  • Today's Change-0.05 / -3.45%
  • Shares traded184.04m
  • 1 Year change-28.21%
  • Beta0.9927
Data delayed at least 15 minutes, as of Jul 10 2020 08:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Sichuan Hebang Biotechnology Co., Ltd., formerly Sichuan Hebang Corporation Limited, is a China-based company, principally engaged in the manufacture of chemical products. The Company operates its businesses through three segments, including Agriculture segment, Chemical segment and New Materials segment. The Agriculture segment provides chemical pesticides, feed nutrients, biological pesticide machines and other biological products. The Chemical segment provides sodium carbonate, sodium chloride, salt and phosphate. The New Materials segment provides smart glass, specialty glass and carbon fibers. It distributes its products within domestic market and to overseas markets.

  • Revenue in CNY (TTM)5.56bn
  • Net income in CNY372.44m
  • Incorporated2002
  • Employees4.81k
  • Location
    Sichuan Hebang Biotechnology Co LtdWutongqiao DistrictLESHAN 614801ChinaCHN
  • Phone+86 2 862050230
  • Fax+86 2 862050290
  • Websitehttp://www.hebang.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Huayi Group Corp Ltd33.54bn113.75m11.38bn13.02k110.850.6593--0.33920.05120.051216.288.620.72197.3613.562,576,418.000.10321.890.20083.688.227.940.1431.800.9005--0.486532.01-15.022.19-65.42-13.415.90-7.79
Sichuan Hebang Biotechnology Co Ltd5.56bn372.44m12.36bn4.81k33.201.10--2.220.04220.04220.63011.270.39863.478.761,156,214.002.463.003.033.7521.4423.116.178.120.71384.560.152733.24-0.664322.2542.35-5.11-1.56--
Zhejiang Jiahua Energy Chemcl Indu CoLtd5.13bn1.13bn13.93bn1.36k12.131.93--2.710.80120.80123.635.030.59097.079.703,777,442.0013.0712.9715.7817.5634.3430.7422.1119.331.3892.150.067332.63-4.199.6611.5216.2034.0839.26
Data as of Jul 10 2020. Currency figures normalised to Sichuan Hebang Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

12.90%Per cent of shares held by top holders
HolderShares% Held
Western Leadbank Fund Management Co., Ltdas of 31 Mar 2020676.53m7.66%
Beixin Ruifeng Fund Management Co., Ltd.as of 31 Mar 2019250.47m2.84%
CCB Principal Asset Management Co., Ltd.as of 31 Mar 202072.71m0.82%
China Southern Asset Management Co., Ltd.as of 31 Dec 201968.57m0.78%
Canada Pension Plan Investment Boardas of 31 Mar 201932.68m0.37%
The Vanguard Group, Inc.as of 31 May 202014.92m0.17%
China Asset Management Co., Ltd.as of 31 Dec 20196.85m0.08%
GF Fund Management Co., Ltd.as of 31 Dec 20196.24m0.07%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 20196.00m0.07%
Harvest Fund Management Co., Ltd.as of 31 Dec 20194.09m0.05%
More ▼
Data from 30 Jun 2019 - 02 Jul 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.